Financing includes strong support from Pennsylvania investors and former Major League Baseball All-Star Andre Ethier

融资包括来自宾夕法尼亚州投资者和前美国职业棒球大联盟全明星球员安德烈·伊西尔的强力支持

WEST CHESTER, Pa.

宾夕法尼亚州西切斯特

,

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ -- Meduloc, an orthopedic medical device company commercializing an innovative flexible nitinol intramedullary fracture fixation platform, today announced the closing of its $4 million Series B financing.

/美通社/ -- 骨科医疗器械公司Meduloc今日宣布完成400万美元的B轮融资。该公司正致力于商业化一款创新的柔性镍钛合金髓内骨折固定平台。

The round was led by GenHenn Capital, with participation from Life Sciences Greenhouse Investments (LSGI)

本轮融资由GenHenn Capital领投，Life Sciences Greenhouse Investments（LSGI）参投。

1

1

, Ben Franklin Technology Partners of Southeastern Pennsylvania

宾夕法尼亚州东南部本·富兰克林技术合作伙伴

2

2

, Broad Street Angels and former Los Angeles Dodgers player Andre Ethier, together with additional existing and new investors.

、Broad Street Angels 以及前洛杉矶道奇队球员安德烈·伊西尔，连同其他现有及新投资者。

Continue Reading

继续阅读

Meduloc’s flexible nitinol intramedullary implant positioned within the bone

Meduloc 的柔性镍钛髓内植入物置于骨内

The participation of LSGI, Ben Franklin Technology Partners of Southeastern Pennsylvania and Broad Street Angels reflects strong support from the Pennsylvania investment community, including significant backing from the Greater Philadelphia region.

LSGI、宾夕法尼亚州东南部的本·富兰克林技术合作伙伴以及百老汇天使投资集团的参与，反映了宾夕法尼亚州投资社区的强力支持，其中包括来自大费城地区的重要背书。

The financing will support Meduloc's controlled alpha launch, continued generation of clinical evidence and development of the commercial infrastructure required to bring its fracture fixation platform to a broader range of surgeons and patients.

此次融资将支持Meduloc公司开展可控的Alpha阶段发布，持续生成临床证据，并建设将其骨折固定平台推广至更广泛外科医生和患者群体所需的商业基础设施。

'Closing this financing is a significant milestone for Meduloc as we move from product development and regulatory clearance into controlled commercialization,' said Sarah Sachinis, President and CEO of Meduloc. 'We are extremely grateful for the confidence and support of our investors, and particularly proud of the strong backing we have received from the Greater Philadelphia and Pennsylvania life sciences and investment communities.

Meduloc总裁兼首席执行官Sarah Sachinis表示：“完成本轮融资对Meduloc而言是一个重要的里程碑，标志着我们从产品研发和监管审批阶段迈向可控的商业化阶段。我们非常感谢投资者们的信任与支持，并特别自豪地获得了大费城地区及宾夕法尼亚州生命科学界和投资界的强力支持。”

This capital enables us to begin our alpha launch, build meaningful clinical experience and establish the foundation for broader adoption across adult and pediatric fracture care.'.

这笔资金使我们能够启动Alpha版本发布，积累有意义的临床经验，并为在成人和儿童骨折护理领域的更广泛应用奠定基础。

Meduloc's FDA-cleared, sterile, single-use system uses a flexible nitinol intramedullary implant designed to provide fracture stability while preserving anatomy and avoiding joint violation in certain applications. The platform can be used across a range of upper- and lower-extremity long-bone fracture applications in adult and pediatric patients..

Meduloc 获得美国食品药品监督管理局（FDA）许可的无菌一次性系统，采用柔性镍钛髓内植入物，旨在在特定应用中提供骨折稳定性，同时保留解剖结构并避免侵犯关节。该平台可用于成人和儿科患者上下肢长骨骨折的多种治疗场景。

'Meduloc has developed a differentiated technology with the potential to address important needs in fracture fixation,' said Bill Hagaman of GenHenn Capital. 'With FDA clearance, encouraging early clinical experience and an experienced team, the company has reached an exciting inflection point. We are pleased to lead this financing and support Meduloc as it enters its next phase of growth.'.

GenHenn Capital 的 Bill Hagaman 表示：“Meduloc 开发出了一项差异化技术，有望满足骨折固定领域的重要需求。凭借 FDA 的许可、令人鼓舞的早期临床经验以及一支经验丰富的团队，公司已迎来一个激动人心的转折点。我们很高兴能领投此次融资，并支持 Meduloc 进入其下一个增长阶段。”

'As a former professional athlete, I have seen how injuries and recovery can affect both performance and quality of life,' said Andre Ethier. 'Meduloc's approach stood out to me because of its potential to provide surgeons with an innovative treatment option and help patients return to the activities that matter to them.

“作为一名前职业运动员，我亲眼目睹了伤病和康复过程如何影响运动表现和生活质量，”安德烈·伊瑟尔表示。“Meduloc的方法之所以引起我的关注，是因为它有望为外科医生提供一种创新的治疗选择，并帮助患者重返他们珍视的活动。”

I'm excited to support the team as it brings this technology into broader clinical use.'.

“我很兴奋能够支持团队将这项技术广泛应用于临床。”

Meduloc expects to begin its controlled alpha launch in early August 2026, working with a select group of orthopedic surgeons and institutions to build clinical experience across multiple fracture applications and collect surgeon feedback to support future commercial expansion.

Meduloc 预计将于 2026 年 8 月初启动其受控的 alpha 版本发布，与精选的骨科医生和机构合作，积累多种骨折应用场景下的临床经验，并收集外科医生的反馈，以支持未来的商业化扩展。

¹ This project was financed in part by a grant to Life Sciences Greenhouse Investments from the Commonwealth of Pennsylvania.

¹ 本项目部分资金由宾夕法尼亚联邦向生命科学温室投资公司提供的拨款资助。

2

2

This project was financed in part by a grant to Ben Franklin Technology Partners of Southeastern Pennsylvania from the Commonwealth of Pennsylvania.

本项目部分资金由宾夕法尼亚联邦向宾夕法尼亚州东南部本·富兰克林技术合作伙伴提供的拨款资助。

About Meduloc

关于 Meduloc

Meduloc is an orthopedic medical device company focused on advancing fracture fixation through an innovative flexible nitinol intramedullary platform. Its FDA-cleared, sterile, single-use system is designed for use across a range of long-bone fracture applications in adult and pediatric patients. Meduloc's technology is intended to provide stable fixation while preserving anatomy and offering surgeons a versatile alternative for fracture treatment..

Meduloc 是一家骨科医疗器械公司，专注于通过创新的柔性镍钛诺髓内平台推进骨折固定技术。其获得美国食品药品监督管理局（FDA）许可的无菌一次性系统，旨在用于成人和儿科患者的各类长骨骨折治疗。Meduloc 的技术旨在提供稳定的固定效果，同时保护解剖结构，并为外科医生提供一种多功能的骨折治疗替代方案。

For more information, visit

更多信息，请访问

www.meduloc.com

www.meduloc.com

SOURCE Meduloc

来源 Meduloc

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示